Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy

被引：0
|
作者：
Allen, Pamela B. [1 ]
Bazzi, Latifa [2 ]
Zhang, Bin [3 ]
Chen, Qing [4 ]
Slonim, Liron Barnea [4 ]
Savas, Hatice [5 ]
Advani, Ranjana H. [6 ]
Evens, Andrew M. [7 ]
Pro, Barbara [8 ]
Karmali, Reem [9 ]
Mou, Eric [10 ]
Eisner, Robert [11 ]
Bayer, Robert [11 ]
Gordon, Leo I. [12 ]
Winter, Jane N. [13 ]
机构：
[1] Emory Univ, Dept Hematol, Sch Med, Decatur, GA USA
[2] Northwestern, Biostatist, Chicago, IL USA
[3] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol & Oncol, Chicago, IL USA
[4] Northwestern Hosp, Pathol, Chicago, IL USA
[5] Northwestern, Radiol, Chicago, IL USA
[6] Stanford Univ, Dept Med, Div Oncol & Hematol, Stanford, CA USA
[7] Rutgers Canc Inst, New Brunswick, NJ USA
[8] Columbia Univ, Lymphoma Program, Div Hematol & Oncol, New York, NY USA
[9] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[10] Univ Iowa, Div Hematol Oncol & Blood & Marrow Transplantat, Iowa City, IA USA
[11] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[12] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA
[13] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-208680
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1664 / 1665
页数：2
相关论文
共 27 条
  • [21] High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation (auto-SCT) Versus CHOP Regimen in Patients with Untreated Aggressive Non-Hodgkin's Lymphoma: An Update of the GOELAMS 072 Trial with a Median Follow-up of 9.8 Years
    Gastinne, Thomas
    Damaj, Gandhi
    Lamy, Thierry
    Ifrah, Norbert
    Deconinck, Eric
    Gressin, Remy
    Colombat, Philippe
    Delwail, Vincent
    Berthou, Christian
    Rossi, Jean Francois
    Harousseau, Jean Luc
    Milpied, Noel-Jean
    BLOOD, 2008, 112 (11) : 286 - 286
  • [22] 11-Yr follow-up of 184 non-Hodgkin's lymphoma (NHL) patients treated with high-dose sequential (HDS) chemotherapy and autograft: Highest response and best outcome in germinal-center derived subtypes.
    Tarella, C
    Caracciolo, D
    Ladetto, M
    Zallio, F
    Cuttica, A
    Ricca, I
    Gavarotti, P
    Bergui, L
    Corradini, P
    Pileri, A
    BLOOD, 2000, 96 (11) : 796A - 796A
  • [23] Long-term follow-up of patients treated in a phase 2 trial with MyVax® personalized immunotherapy (recombinant Id-KLH with GM-CSF) after chemotherapy as initial treatment for follicular non-Hodgkin's lymphoma (NHL).
    Timmerman, JM
    Vose, J
    Levy, R
    Mayo, M
    Denney, D
    BLOOD, 2005, 106 (11) : 685A - 686A
  • [24] Long-term events in adult patients with clinical stage IA-IIa nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin,vinblastine, and dacarbazine and adjuvant radiotherapy: A single-institution 15-year follow-up
    Brusamolino, Ercole
    Baio, Ambrogia
    Orlandi, Ester
    Arcaini, Luca
    Passamonti, Francesco
    Griva, Vassiliki
    Casagrande, William
    Pascutto, Cristiana
    Franchini, Pietro
    Lazzarino, Mario
    CLINICAL CANCER RESEARCH, 2006, 12 (21) : 6487 - 6493
  • [25] Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial
    Russell, James
    Collins, Angela
    Fowler, Alexis
    Karanth, Mamatha
    Saha, Chandan
    Docherty, Suzanne
    Padayatty, Joseph
    Maw, Kyaw
    Lentell, Isabel
    Cooke, Lisa
    Hodson, Andrew
    Shah, Nimish
    Sadullah, Shalal
    Grigoropoulos, Nicholas
    Qian, Wendi
    Kirkwood, Amy A.
    Uttenthal, Benjamin J.
    Johnson, Peter
    Follows, George A.
    ANNALS OF HEMATOLOGY, 2021, 100 (04) : 1049 - 1058
  • [26] Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial
    James Russell
    Angela Collins
    Alexis Fowler
    Mamatha Karanth
    Chandan Saha
    Suzanne Docherty
    Joseph Padayatty
    Kyaw Maw
    Isabel Lentell
    Lisa Cooke
    Andrew Hodson
    Nimish Shah
    Shalal Sadullah
    Nicholas Grigoropoulos
    Wendi Qian
    Amy A. Kirkwood
    Benjamin J. Uttenthal
    Peter Johnson
    George A. Follows
    Annals of Hematology, 2021, 100 : 1049 - 1058
  • [27] A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Hess, Georg
    Gaidano, Gianluca
    Provencio, Mariano
    Nagy, Zsolt
    Robak, Tadeusz
    Maddocks, Kami J.
    Buske, Christian
    Ambarkhane, Sumeet
    Brugger, Wolfram
    Dirnberger-Hertweck, Maren
    Tillmanns, Sascha
    Weirather, Johannes
    Blum, Kristie
    BLOOD, 2019, 134
123